TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26809022

Group type: EXPERIMENTAL
Intervention: Hybrid therapy (esomeprazole 20 mg and amoxicillin 1000 mg twice daily for 14 days with the addition of clarithromycin 500 mg and tinidazole 500 mg twice daily for the final 7 days)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Hybrid therapy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Dual clarithromycin and metronidazole resistance
Number of subjects: 196
Study: 24188287

Group type: EXPERIMENTAL
Intervention: Instructed emotion regulation using reappraisal while watching a sadness-inducing film clip
Number of subjects: 152

Group type: COMPARATOR
Intervention: Spontaneous emotion regulation (no specific instructions)
Number of subjects: 152
Study: 21723359

Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) 2R→3R polymorphism
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Serine hydroxymethyltransferase (SHMT1) 1420C→T polymorphism
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C→T polymorphism
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Mood assessment using the depression subscale of the Symptom Checklist 90
Number of subjects: 1595
Study: 21503180

Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caffeine 15 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17173248

Group type: EXPERIMENTAL
Intervention: CTGF mRNA expression in diabetic nephropathy (DN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TGF-beta 1 mRNA expression in diabetic nephropathy (DN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type IV collagen mRNA expression in diabetic nephropathy (DN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of CTGF, TGF-beta 1, and type IV collagen mRNA expressions
Number of subjects: 0
Study: 12717205

Group type: EXPERIMENTAL
Intervention: Tacrolimus + Sirolimus
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Tacrolimus + MMF
Number of subjects: 361
Study: 11026396

Group type: EXPERIMENTAL
Intervention: 40 g of glucose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Artificially sweetened beverage
Number of subjects: 20
Study: 9232256

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506) with methotrexate
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cyclosporine with methotrexate
Number of subjects: 70
Study: 1587426

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (500 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (three times weekly for 1 month)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Number of subjects: 30
Study: 2871286

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler ultrasound scanning
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mitral flow ratios greater than 2
Number of subjects: 20
Study: 30594482

Group type: EXPERIMENTAL
Intervention: Follitropin delta
Number of subjects: 701

Group type: COMPARATOR
Intervention: Follitropin alfa
Number of subjects: 701
Study: 27588932

Group type: EXPERIMENTAL
Intervention: 20 units of oxytocin diluted in 500 mL of lactated Ringer solution
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 30 units of oxytocin diluted in 500 mL of lactated Ringer solution
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 40 units of oxytocin diluted in 500 mL of lactated Ringer solution
Number of subjects: 189
Study: 26061985

Group type: EXPERIMENTAL
Intervention: Fluoridated varnish (Clinpro)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-etch primer system (Transbond Plus Self‐Etch Primer)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resin infiltrate (ICON)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intact enamel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Demineralized enamel
Number of subjects: 50
Study: 23117015

Group type: EXPERIMENTAL
Intervention: Moderate treadmill training (repetitive intervals to moderate claudication pain)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pain-free treadmill training (repetitive intervals to onset of claudication pain)
Number of subjects: 60
Study: 21586693

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Patients with early ST
Number of subjects: 401

Group type: COMPARATOR
Intervention: Patients without early ST
Number of subjects: 401
Study: 19796737

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 3602

Group type: COMPARATOR
Intervention: bivalirudin
Number of subjects: 3602
Study: 16426270

Group type: EXPERIMENTAL
Intervention: SNP rs1043994
Number of subjects: 97

Group type: COMPARATOR
Intervention: NOTCH3 gene mutations in exons 3 and 4
Number of subjects: 97
Study: 15451899

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (1.6 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Carrier solution (control)
Number of subjects: 38
Study: 11253562

Group type: EXPERIMENTAL
Intervention: Budipine (3 x 20 mg/d)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Amantadine (3 x 100 mg/d)
Number of subjects: 53
Study: 9306302

Group type: EXPERIMENTAL
Intervention: Therapeutic community (TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community residence (CR)
Number of subjects: 0
Study: 8173712

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (intravenous tissue plasminogen activator in 561 patients, urokinase in 102 patients, combination of tissue plasminogen activator and urokinase in 147 patients)
Number of subjects: 810
Study: 2946815

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Streptozotocin plus mitomycin C plus 5-FU (original SMF)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses
Number of subjects: 133
Study: 31365489

Group type: EXPERIMENTAL
Intervention: Ringer's acetate solution infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Infusions in normovolemic state
Number of subjects: 20
Study: 29226545

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oxygen (control)
Number of subjects: 240
Study: 27923439

Group type: EXPERIMENTAL
Intervention: Repeated readings (RR)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Wide reading (WR)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Business as usual
Number of subjects: 168
Study: 25019535

Group type: EXPERIMENTAL
Intervention: Therapist orienting the patient toward affect
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sense of self
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Therapist intervention
Number of subjects: 50
Study: 22161726

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 338

Group type: COMPARATOR
Intervention: Reduction in UI frequency
Number of subjects: 338
Study: 19996309

Group type: EXPERIMENTAL
Intervention: Intranasal insulin administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9
Study: 18221410

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg o.d.
Number of subjects: 18325

Group type: COMPARATOR
Intervention: naproxen 500 mg b.d.
Number of subjects: 18325

Group type: COMPARATOR
Intervention: ibuprofen 800 mg t.d.s.
Number of subjects: 18325
Study: 16838125

Group type: EXPERIMENTAL
Intervention: IVGTT
Number of subjects: 40
Study: 12615747

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 1290000

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (general)
Number of subjects: 1290000
Study: 10850829

Group type: EXPERIMENTAL
Intervention: Individuals with spinal cord injury (SCI)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control population (ambulatory adults)
Number of subjects: 364
Study: 9190631

Group type: EXPERIMENTAL
Intervention: Dialysis fluid containing acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysis fluid containing bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8249554

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular (im) morphine
Number of subjects: 31
Study: 3902378

Group type: EXPERIMENTAL
Intervention: Equine antisera (anti-diencephalon and anti-stomach tissue)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 40
Study: 29237235

Group type: EXPERIMENTAL
Intervention: everolimus + reduced tacrolimus (EVR+rTAC)
Number of subjects: 284

Group type: COMPARATOR
Intervention: standard tacrolimus (TAC Control)
Number of subjects: 284
Study: 26693858

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (0 mg/kg)
Number of subjects: 14
Study: 24955739

Group type: EXPERIMENTAL
Intervention: Oral valproic acid (VPA) 500mg once daily for 1 year
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study: 22549680

Group type: EXPERIMENTAL
Intervention: Frankel's functional regulator 1b
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 83
Study: 20395080

Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study: 18554232

Group type: EXPERIMENTAL
Intervention: Nonexclusive control questions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Exclusive control questions
Number of subjects: 120
Study: 15914346

Group type: EXPERIMENTAL
Intervention: Infants of diabetic mothers (IDMs)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Macrosomic infants of nondiabetic mothers
Number of subjects: 83

Group type: COMPARATOR
Intervention: Infants of pregestational diabetic mothers
Number of subjects: 83
Study: 12695832

Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s without flush (Group 1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s with a 30-ml flush (Group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s without flush (Group 3)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s with a 30-ml flush (Group 4)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Use of a flush
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Higher injection rate protocols (Groups 1 and 2)
Number of subjects: 180
Study: 10328403

Group type: EXPERIMENTAL
Intervention: Automated perimetry and daytime IOP curve taken every second month during the 2-year follow-up
Number of subjects: 82
Study: 7813100

Group type: EXPERIMENTAL
Intervention: Alphaglobin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sandoglobulin/Gamimune
Number of subjects: 21
Study: 1661447

Group type: EXPERIMENTAL
Intervention: Standard Heparin (SH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 0
Study: 6760376

Group type: EXPERIMENTAL
Intervention: Endoscopic cholangiography
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transhepatic cholangiography
Number of subjects: 52
Study: 31761447

Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 26
Study: 30012389

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (n=47)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mock laser control (n=49)
Number of subjects: 96
Study: 27358159

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronic acid (HA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of oxygen ozone (O2O3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of hyaluronic acid (HA) and oxygen ozone (O2O3)
Number of subjects: 70
Study: 24776953

Group type: EXPERIMENTAL
Intervention: Alternative monotherapy with a second AED (Group A)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Add-on treatment with a second AED (Group B)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Quality of life based on the Quality Of Life In Epilepsy scale
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Tolerability
Number of subjects: 264
Study: 22570370

Group type: EXPERIMENTAL
Intervention: Adherence and Intensification of Medications intervention
Number of subjects: 4099

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4099
Study: 19493565

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 1911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1911
Study: 17456583

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oseltamivir (all doses)
Number of subjects: 28
Study: 15156331

Group type: EXPERIMENTAL
Intervention: Potentially unstable fixation group (n=15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stable fixation group (n=25)
Number of subjects: 40
Study: 12487226

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg for ages 6 to < 14 years; 10 mg for > 14 years)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 16
Study: 9660559

Group type: EXPERIMENTAL
Intervention: Dynamic k-space filling with bolus chase 3D MRDSA using a 25-ml gadolinium dose and a multiple-phase 3D fast gradient-echo sequence.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Complex subtraction technique for image acquisition.
Number of subjects: 7
Study: 7665422

Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 16
Study: 2539648

Group type: EXPERIMENTAL
Intervention: IE (ifosfamide, 1.5 g/m2, days 1 through 5; etoposide, 120 mg/m2, days 3 through 5)
Number of subjects: 718

Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, 600 mg/m2, days 1 and 2; doxorubicin, 50 mg/m2, day 1; vincristine, 2 mg, day 1)
Number of subjects: 718

Group type: COMPARATOR
Intervention: PE (cisplatin, 90 mg/m2, day 1; etoposide, 150 mg/m2, days 3 through 5)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: IAV (ifosfamide, 2 g/m2, days 1 to 5; doxorubicin, 25 mg/m2, days 1 and 2; vincristine, 2 mg, day 1)
Number of subjects: 718

Group type: COMPARATOR
Intervention: PE or JE (carboplatin, 300 mg/m2, day 1; etoposide, 120 mg/m2, days 1 to 3)
Number of subjects: 718
Study: 362519

Group type: EXPERIMENTAL
Intervention: Oral dose of 1 g twice daily for one day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg/kg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Higher dosage regime (1 g twice daily)
Number of subjects: 22
Study: 30825563

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional debridement therapy
Number of subjects: 26
Study: 28093383

Group type: EXPERIMENTAL
Intervention: Standardised minimal acupuncture at LI4
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Semi-standardised individual acupuncture inspired by Traditional Chinese Medicine
Number of subjects: 147

Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 147
Study: 26376691

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study: 23572225

Group type: EXPERIMENTAL
Intervention: LATG with DST
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 21-mm EEA stapler
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 25-mm EEA stapler
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open total gastrectomy
Number of subjects: 52
Study: 21376474

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 19671476

Group type: EXPERIMENTAL
Intervention: PR‐Porcelain Repair Kit (Bisco) [etching with 9.5% hydrofluoric acid+silanization+adhesive]
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CJ‐CoJet Repair Kit (3M ESPE) [(chairside silica coating with 30microm SiO(2)+silanization (ESPE)‐Sil)+adhesive (Visio‐Bond)]
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CL‐Clearfil Repair Kit [diamond surface roughening, etching with 40% H(3)PO(4)+Clearfil Porcelain Bond Activator+Clearfil SE Bond]
Number of subjects: 30
Study: 17904297

Group type: EXPERIMENTAL
Intervention: 0.5mg testosterone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15203264

Group type: EXPERIMENTAL
Intervention: Radiation group (beta-radiation with a (188)Re-filled balloon catheter system)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-stented adjacent segments)
Number of subjects: 20
Study: 11181985

Group type: EXPERIMENTAL
Intervention: Active NCPAP therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sub-therapeutic NCPAP therapy
Number of subjects: 0
Study: 9554631

Group type: EXPERIMENTAL
Intervention: RESPIMAT device delivering fenoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI alone delivering fenoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI with Aerochamber delivering fenoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RESPIMAT device delivering flunisolide
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI plus spacer delivering flunisolide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RESPIMAT device with baffle delivering flunisolide
Number of subjects: 0
Study: 7851269

Group type: EXPERIMENTAL
Intervention: Diabetic subjects (mean glomerular filtration rate 216 ml/min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diabetic subjects (corrected for body size, mean glomerular filtration rate 165.6 ml/min per 1.73 m2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diabetic subjects (albumin excretion median 61 mg/day)
Number of subjects: 15
Study: 3072940

Group type: EXPERIMENTAL
Intervention: HR-6 solutions containing adenosine triphosphate (0.5 or 5 mg/ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29505742

Group type: EXPERIMENTAL
Intervention: Immediate rotator cuff repair (Group 1, n = 44)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Delayed rotator cuff repair after 6 months of nonoperative treatment (Group 2, n = 34)
Number of subjects: 78
Study: 27640126

Group type: EXPERIMENTAL
Intervention: Insert (two-page evidence-based article)
Number of subjects: 23508

Group type: EXPERIMENTAL
Intervention: Outsert (short, directive message)
Number of subjects: 23508

Group type: EXPERIMENTAL
Intervention: Insert + Outsert
Number of subjects: 23508

Group type: COMPARATOR
Intervention: Control (no educational messages)
Number of subjects: 23508
Study: 24072718

Group type: EXPERIMENTAL
Intervention: Longitudinal continuity of care (COC) with the same PCP
Number of subjects: 4393

Group type: EXPERIMENTAL
Intervention: Low Modified Modified Continuity Index (MMCI)
Number of subjects: 4393

Group type: EXPERIMENTAL
Intervention: Abbreviated duration of PCP care (< 1 year)
Number of subjects: 4393
Study: 22087736

Group type: EXPERIMENTAL
Intervention: Jebsen‐Taylor hand function test (JHFT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Motoric performance test (MLS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Number connection test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient self-assessment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (D)
Number of subjects: 90
Study: 20736152

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily) alone (DRVrMono)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Darunavir/ritonavir with nucleoside analogues (DRVrNRTI)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRVrMono)
Number of subjects: 256
Study: 18511605

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg once daily)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 17214382

Group type: EXPERIMENTAL
Intervention: Repetition priming with dynamic chimeras
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition priming with static chimeras
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition priming with half-faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition priming with chimeras (restricted to recognized faces)
Number of subjects: 0
Study: 12751846

Group type: EXPERIMENTAL
Intervention: Autism group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-exposed to labelled individual tones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children with autism
Number of subjects: 0
Study: 11369670

Group type: EXPERIMENTAL
Intervention: Propionic acid at 59.15 p.p.m.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propionic acid at 8.22 p.p.m.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propionic acid at 1.14 p.p.m.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 24
Study: 8994938

Group type: EXPERIMENTAL
Intervention: Cognitive performance measured by Mini Mental State Examination, Benton Visual Retention Test, and Isaacs Set Test at baseline screening.
Number of subjects: 2726
Study: 8427728

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire (four different types)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire (most reliable type from first study)
Number of subjects: 140
Study: 2888302

Group type: EXPERIMENTAL
Intervention: Carvedilol, 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carvedilol, 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29502805

Group type: EXPERIMENTAL
Intervention: HD201
Number of subjects: 73

Group type: COMPARATOR
Intervention: EU‐trastuzumab
Number of subjects: 73